title: Infliximab as salvage therapy in paediatric intestinal transplant with steroid- and thymoglobulin-resistant late acute rejection.
authors.affiliation: Division of Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: De Greef
authors.forename: Yaron
authors.initials: Y
authors.lastname: Avitzur
authors.forename: David
authors.initials: D
authors.lastname: Grant
authors.forename: Maria
authors.initials: M
authors.lastname: De-Angelis
authors.forename: Vicky
authors.initials: V
authors.lastname: Ng
authors.forename: Nicola
authors.initials: N
authors.lastname: Jones
authors.forename: Bo
authors.initials: B
authors.lastname: Ngan
authors.forename: Rivka
authors.initials: R
authors.lastname: Shapiro
authors.forename: Ran
authors.initials: R
authors.lastname: Steinberg
authors.forename: Juan C
authors.initials: JC
authors.lastname: Gana
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000961:Antilymphocyte Serum / Q000494:pharmacology; D000077552:Basiliximab; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000494:pharmacology; D000069285:Infliximab; D007422:Intestines / Q000473:pathology / Q000637:transplantation*; D008297:Male; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000069285:Infliximab; C512542:thymoglobulin